Maged Hosny, MD
Rheumatology · Dover, DENPI 1326003351
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 66 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $825 and has fallen 91.2% since, to $72 in 2023.
Across 66 payments — averaging $18.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$193
- UCB, Inc.$181
- AbbVie$106
- Johnson & Johnson$101
- Novartis$100
- Pfizer$87
- plus $439 from 12 others
What the payments were for
- Food & beverage$1,208100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 11 | $193 |
| UCB, Inc. | 8 | $181 |
| AbbVie | 7 | $106 |
| Johnson & Johnson | 6 | $101 |
| Novartis | 5 | $100 |
| Pfizer | 6 | $87 |
| Lilly USA, LLC | 4 | $79 |
| Organon | 2 | $69 |
| E.r. Squibb & Sons, L.L.C. | 4 | $67 |
| Medexus Pharma, Inc. | 3 | $40 |
| Hikma Pharmaceuticals USA | 2 | $37 |
| GSK | 2 | $35 |
| Mallinckrodt Enterprises LLC | 1 | $25 |
| Bristol Myers Squibb | 1 | $21 |
| Genentech USA, Inc. | 1 | $19 |
| Scilex Pharmaceuticals Inc. | 1 | $18 |
| Mallinckrodt Hospital Products Inc. | 1 | $17 |
| Pacira Therapeutics, Inc. | 1 | $14 |
How this compares
Too few rheumatology providers in Delawareto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 171 | $1,372,858 |
| Enbrel SureclickEtanercept | 97 | $857,757 |
| EnbrelEtanercept | 38 | $410,725 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 27 | $318,052 |
| Orencia ClickjectAbatacept | 41 | $308,125 |
| Cimzia (2 Pack)Certolizumab Pegol | 17 | $283,655 |
| RinvoqUpadacitinib | 32 | $218,373 |
| Humira PenAdalimumab | 30 | $204,083 |
| Humira(Cf)Adalimumab | 16 | $154,215 |
| SimponiGolimumab | 19 | $147,800 |
| Xeljanz XrTofacitinib Citrate | 22 | $134,683 |
| BenlystaBelimumab | 18 | $126,517 |
| Teriparatide | 22 | $111,003 |
| OtezlaApremilast | 18 | $108,577 |
| ActemraTocilizumab | 13 | $68,434 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenEnbrel, Otezla | $193 | $519,30356 claims |
| AbbVieRinvoq, Humira(Cf), Savella | $106 | $384,35660 claims |
| UCB, Inc.Cimzia (2 Pack) | $181 | $283,65517 claims |
| Johnson & JohnsonSimponi | $101 | $147,80019 claims |
| GSKBenlysta | $35 | $126,51718 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $18 | $1,99960 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few rheumatology providers in Delawareon file to place this against a meaningful peer group, so we don't.
Other rheumatology in Dover
- Jinsong ZhangDover$11K
- Surjeet DheerDover$7K
- Yvan Maque AcostaDover$5K
- Robert MoyerDover$3K
- Sherron BowieDover$19
- Jose PandoLewes$93K
- Lourdes AponteLewes$20K
- Philip SchwartzWilmington$10K
- Ivonne HerreraSeaford$9K
- Amy ZhangNewark$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.